Jillian Barker

Contact

• workRoom CS6 The University of Nottingham Medical School
  Queen's Medical Centre
  Nottingham
  NG7 2UH
  UK
• work0115 82 30085
• fax0115 82 30081
• jillian.baker@nottingham.ac.uk

Expertise Summary

After obtaining her medical degree and 4 years clinical experience, Jill Baker was awarded a Wellcome Trust Clinical Training Fellowship to undertake a PhD in molecular pharmacology in the Institute of Cell Signalling at the University of Nottingham (2001-2004). Jill then secured a Wellcome Trust Clinician Scientist Fellowship (2004-2009) to enable her to continue with her research on ß-adrenoceptors whilst continuing her specialist clinical training in respiratory medicine. Jill is currently the 2008 British Pharmacology Society's Bill Bowman travelling lecturer and is a previous winner of the British Thoracic Society's Young Investigator of the Year award (2003). She also serves on the Editorial Board of the British Journal of Pharmacology.

Selected Publications

• BAKER, J. G., 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors British Journal of Pharmacology. VOL 144(NUMB 3), 317-322
• BAKER, J.G, HALL, I.P. and HILL, S.J., 2003. Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor Molecular Pharmacology. 63(6), 1312-1321
• BAKER, J.G., HALL, I.P. and HILL, S.J., 2003. Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses Molecular Pharmacology. 64(3), 679-688
• BAKER, J.G, 2005. Evidence for a secondary state of the human beta3-adrenoceptor. Molecular Pharmacology. 68(6), 1645-1655

• View all publications

• WARNE T, MOUKHAMETZIANOV R, BAKER JG, NEHME R, EDWARDS PC, LESLIE, AGW, SCHERTLER GFX, TATE CG, 2011. The structural basis for agonist and partial agonist action on a β1-adrenergic receptor. Nature. 469(7329), 241-4
• JILLIAN G BAKER, RICHARD GW PROUDMAN and CHRISTOPHER G TATE, 2011. The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (β36) deletions essential for crystallisation of the turkey β-adrenoceptor NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. 384, 71-91
• JILLIAN G BAKER, PHILIP KEMP, JULIE MARCH, LAURICE FRETWELL, STEPHEN J HILL and SHEILA M GARDINER, 2011. Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses. FASEB Journal. 25(12), 4486-4497
• JILLIAN G BAKER, LUKE A ADAMS, KAROLINA SALCHOW, #S, SHAILESH N MISTRY, , RICHARD J MIDDLETON, STEPHEN J HILL, BARRIE KELLAM and BARRIE KELLAM, 2011. Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY)-labeled fluorescent ligands for the human beta-adrenoceptors. J Med Chem. 54, 6874-6887
• JILLIAN G BAKER, STEPHEN J HILL and ROGER J SUMMERS, 2011. Evolution of β-blockers - from anti-anginal drugs to ligand-directed signalling TRENDS IN PHARMACOLOGICAL SCIENCES. 32, 227-234
• BAKER, JILLIAN G, MIDDLETON, RICHARD, ADAMS, LUKE, MAY, LAUREN T, BRIDDON, STEPHEN J, KELLAM, BARRIE and HILL, STEPHEN J, 2010. Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands. British Journal of Pharmacology. 159(4), 772-86
• BAKER, JILLIAN G, 2010. The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. British journal of pharmacology. 160(5), 1048-61
• BAKER JG, 2010. A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors PLoS ONE. 5(11):, e15487. doi:10.1371/journal.pone.0015487
• BAKER, J G, 2008. A study of antagonist affinities for the human histamine H2 receptor. British Journal of Pharmacology. 153(5), 1011-21
• WARNE, TONY, SERRANO-VEGA, MARIA J, BAKER, JILLIAN G, MOUKHAMETZIANOV, ROUSLAN, EDWARDS, PATRICIA C, HENDERSON, RICHARD, LESLIE, ANDREW G W, TATE, CHRISTOPHER G and SCHERTLER, GEBHARD F X, 2008. Structure of a beta(1)-adrenergic G-protein-coupled receptor. Nature. 454(7203), 486-491
• BAKER, JILLIAN G, 2008. Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells. BMC pharmacology. 8, 9
• , JILLIAN G BAKER, RICHARD GW PROUDMAN, NICOLA HAWLEY, PETER M FISCHER and STEPHEN J HILL, 2008. Role of key transmembrane residues in agonist and antagonist actions at the two conformations of the human β1-adrenoceptor. Molecular Pharmacology. 74, 1246-1260
• MIDDLETON,R, BRIDDON,S.J., CORDEAUX,Y., YATES,A.S., DALE,C.L., GEORGE,M., BAKER,J.G., HILL,S.J. and KELLAM,B., 2007. New Fluorescent Adenosine A(1)-Receptor Agonists That Allow Quantification of Ligand-Receptor Interactions in Microdomains of Single Living Cells. Journal of Medicinal Chemistry. 50(4), 782-793
• BAKER, J.G. and HILL, S.J., 2007. A comparison of the antagonist affinities for the Gi and Gs-coupled states of the human adenosine A1 receptor Journal of Pharmacology and Experimental Therapeutics. 320(1), 218-228
• BAKER, JILLIAN G and HILL, STEPHEN J, 2007. Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends in Pharmacological Sciences. 28(8), 374-81
• BAKER, J.G, 2005. Evidence for a secondary state of the human beta3-adrenoceptor. Molecular Pharmacology. 68(6), 1645-1655
• BAKER, J.G, 2005. Site of action of beta-ligands at the human beta1-adrenoceptor. Journal of Pharmacology and Experimental Therapeutics. 313(3), 1163-1171
• BAKER, J. G., 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors British Journal of Pharmacology. VOL 144(NUMB 3), 317-322
• BAKER, J.G., HALL, I.P. and HILL, S.J., 2004. Temporal characteristics of cAMP response element-mediated gene transcription: requirement for sustained cAMP production Molecular Pharmacology. 65(4), 986-998
• BAKER, J.G, HALL, I.P. and HILL, S.J., 2003. Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor Molecular Pharmacology. 63(6), 1312-1321
• BAKER, J.G., HALL, I.P. and HILL, S.J., 2003. Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling Molecular Pharmacology. 64(6), 1357-1369
• BAKER, J.G., HALL, I.P. and HILL, S.J., 2003. Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses Molecular Pharmacology. 64(3), 679-688
• BAKER, J.G., HALL, I.P. and HILL, S.J., 2003. Pharmacology and direct visualisation of BODIPY-TMR-CGP: a long-acting fluorescent beta2-adrenoceptor agonist British Journal of Pharmacology. 139(2), 232-42
• HILL, S.J. and BAKER, J.G., 2003. The ups and downs of Gs- to Gi-protein switching British Journal of Pharmacology. 138(7), 1188-1190
• BAKER, J.G, HALL, I.P and HILL, S.J., 2002. Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor British Journal of Pharmacology. 137(3), 400-8
• HILL, S J, BAKER, J G and REES, S, 2001. Reporter-gene systems for the study of G-protein-coupled receptors. Current Opinion in Pharmacology. 1(5), 526-32